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The present case report describes a lo-year-old boy with clinical history of steroid-dependent asthma 
who developed severe exacerbation of his respiratory symptoms upon isoniazid administration. 
Subsequent control of his asthma symptoms was re-established and maintained only after isoniazid 
withdrawal. This case is the first to emphasize the dangers of isoniazid administration in patients who 
have asthma. 
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Introduction 
Isoniazid is one of the most useful anti-tuberculosis 
drugs available and is the drug of choice in the 
chemoprophylaxis of tuberculosis (1,2). However, a 
well-recognized adverse effect is its ability to induce 
hepatoxicity (3) and to influence the metabolism of 
a variety of drugs by modulation of the hepatic 
microsomal enzyme systems (45). 
The present case report details the findings in a boy 
with a long-standing clinical history of steroid- 
dependent asthma who developed severe respiratory 
distress requiring maximal pharmacological support 
upon introduction of isoniazid chemoprophylaxis. 
Subsequent control of asthma symptoms was 
re-established and maintained only after isoniazid 
withdrawal. To the authors’ knowledge, this is the 
first reported human case of acute asthma deteriora- 
tion induced by isoniazid. This case highlights the 
importance of considering uncommon side-effects 
when this drug needs to be used in asthmatics who 
necessitate prevention for tuberculosis. 
Case Report 
A lo-year-old boy with brittle steroid-dependent 
asthma was seen with an acute exacerbation of this 
asthma. A diagnosis of asthma was made when he 
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was 5 years old. At the age of 7 years, the young 
patient started to develop recurrent asthma attacks 
which failed to resolve with standard nebulized 
therapy, for which he required oral prednisone and 
occasional domiciliary nasal oxygen. He remained 
well with inhaled salbutamol and beclomethasone 
dipropionate 250,~g two puffs at least four times a 
day and a maintenance dose of 2.5 mg prednisone 
daily. For the last 3 yr, he had had no exacerbation or 
worsening of his asthma. His father had been recently 
diagnosed with active cavitary pulmonary tuberculo- 
sis and he was started on isoniazid (300 mg day - ‘) 
for tuberculosis chemoprophylaxis as his Mantoux 
test was strongly positive with a normal chest roent- 
genogram. Acetylaters status was not assessed. Ten 
days later, his asthma worsened and his peak expira- 
tory flow (PEF) dropped to 80 1 min - ’ (from his best 
value of 240 1 min - ‘) (Fig. 1). Physical examination 
revealed a severely dyspneoic boy with cyanosis. His 
weight (29.5 kg) and height (126 cm) were within 
normal ranges, but there was some abdominal obes- 
ity, and he was flabby with poor musculature. His 
face was plethoric. The pulse rate was 126 beats 
min-‘, blood pressure was 1 lo/80 mmHg, axillary 
temperature was 36.6”C, and respiratory rate was 
36 min-‘. Abdominal striae, ankle oedema and lym- 
phadenopathy were not present. Widespread wheez- 
ing was noted on auscultation of his chest. Cardiac 
examination was unremarkable. Routine laboratory 
investigations were non-contributory (including nor- 
mal liver function tests). Results of lung function tests 
were consistent with severe bronchial obstruction. 
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FIG. 1. Time course of changes in peak expiratory 
flow (PEF) recordings during drug administration. 
Standard nebulized salbutamol (2.5 mg) was admin- 
istered with immediate improvement in his clinical 
picture and spirometry. He was sent home with a 
lo-day course of 12.5 mg prednisone daily. 
The following day, his condition deteriorated fur- 
ther with severe respiratory distress and his PEF was 
unrecordable (Fig. 1). He was immediately treated 
with hydrocortisone intravenously, nasal oxygen, and 
continuous nebulization with high-dose salbutamol 
(10 mg). Prednisone dosage was further increased to 
25 mg day - ‘, and isoniazid was withdrawn. His PEF 
returned to its usual range within 3 days. At that 
time, it was felt that resolution of this acute exacer- 
bation of his asthma was due to the increase in steroid 
dosage, and chemoprophylactic therapy with iso- 
niazid was re-introduced 1 week later. Within 6 days 
from recommencing isoniazid, his asthma deterio- 
rated again and his PEF dropped to 120 1 min - ‘. 
Isoniazid was again stopped with spontaneous 
improvement in his asthma, and PEF values returned 
to their usual range within 24 h. The parents were 
advised to continue his therapeutic programme with 
a maintenance dose of 2.5 mg prednisone daily. 
There were no subsequent problems with his asthma 
control. 
Discussion 
Children and young adults with strongly positive 
Mantoux tests and no BCG history are at risk from 
developing clinical tuberculosis. These children 
should be given chemoprophylaxis with isoniazid for 
6 months which significantly reduces the likelihood of 
subsequent clinical tuberculosis (1,2). 
This case of a boy with a clinical history of 
steroid-dependent asthma, who developed severe 
exacerbations of his symptoms after isoniazid chemo- 
prophylaxis, emphasizes the dangers of isoniazid 
administration in patients who have asthma. To the 
best of the authors’ knowledge, this drug-specific 
response has never been reported in the medical 
literature. Considering that asthma is a rather com- 
mon illness and chemoprophylaxis with isoniazid has 
been prescribed in a large number of individuals, this 
is surprising. A possible explanation is that either 
the treating physicians have not been aware of the 
worsening of asthma in their patients on isoniazid 
chemoprophylaxis (which may be mild in most cases), 
or the adverse reaction described is a very rare one. 
The authors favour this latter hypothesis, as the 
occurrence of an idiosyncratic type of reaction 
against isoniazid is more likely. However, isoniazid- 
induced neurological toxicity with subsequent un- 
balance in the bronchomotor tone cannot be ruled 
out in this child with asthma. 
In these circumstances, suspension of the offending 
drug is the logical approach. In addition, increasing 
steroids remains useful although the extent of the 
increase required is not clear. This young patient 
suffered a severe exacerbation of his asthma requiring 
large doses of oral prednisone and intravenous 
hydrocortisone. As suggested for rifampicin (6), the 
authors would advocate using isoniazid with caution 
in steroid-dependent asthmatics. 
An additional possibility is that the boy might have 
become sensitized to isoniazid. A recent study has 
shown that sensitization to oral isoniazed can occur, 
and that the asthmatic symptoms are caused by an 
1gE antibody specific to isoniazid as a hapten (7,s). 
However, this is unlikely in the present case because 
of the short time of exposure. 
Although clinical observation and accurate history 
taking supported the view that isoniazid was the 
cause of the asthma exacerbations in this young 
patient, other possibilities can not be excluded. Acute 
exacerbations of steroid-dependent asthma in a pre- 
viously stable individual are not unusual. This young 
patient might have been exposed to a flu-like illness. 
However, although no investigations were made to 
prove or exclude a viral infection, his clinical and 
pharmacological history are against this possibility. 
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